MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority
PR Newswire
TORONTO, Feb. 7, 2024
-- MediPharm Labs is the first purpose-built pharmaceutical cannabis company in North America to receive a GMP certificate from the Brazilian Health Regulatory Agency (ANVISA), for production of cannabis finished goods. -- This strengthens MediPharm Labs' position in Brazil to manufacture both API and end products for Brazilian medical cannabis patients. -- Brazil, with a population of 215M, has seen tremendous growth in medical cannabis patients with a 480% increase in prescriptions in 2022.
TORONTO, Feb. 7, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce receipt of
GMP certification for their Barrie, Ontario facility from ANVISA, the governing body of Brazil's pharmaceutical industry.
MediPharm Labs now has GMP certification from the United States FDA, European Union, Australia's TGA and holds a drug establishment license from Health Canada.
This stock was $7.00 per share just 3 years ago !!!